CO2022014587A2 - Compuestos inhibidores de phd, composiciones y uso - Google Patents
Compuestos inhibidores de phd, composiciones y usoInfo
- Publication number
- CO2022014587A2 CO2022014587A2 CONC2022/0014587A CO2022014587A CO2022014587A2 CO 2022014587 A2 CO2022014587 A2 CO 2022014587A2 CO 2022014587 A CO2022014587 A CO 2022014587A CO 2022014587 A2 CO2022014587 A2 CO 2022014587A2
- Authority
- CO
- Colombia
- Prior art keywords
- disease
- pulmonary
- acute
- heart disease
- compositions
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000009304 Acute Kidney Injury Diseases 0.000 abstract 1
- 208000007788 Acute Liver Failure Diseases 0.000 abstract 1
- 206010000804 Acute hepatic failure Diseases 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010019669 Hepatic fibrosis and cirrhosis Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000033626 Renal failure acute Diseases 0.000 abstract 1
- 201000011040 acute kidney failure Diseases 0.000 abstract 1
- 231100000836 acute liver failure Toxicity 0.000 abstract 1
- 206010069351 acute lung injury Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 208000018578 heart valve disease Diseases 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona, en parte, nuevos inhibidores de moléculas pequeñas de PHD, que tienen una estructura de acuerdo con la Fórmula (A), y subfórmulas de estos: (A) o una sal farmacéuticamente aceptable de estos. Los compuestos proporcionados en la presente descripción pueden ser útiles para el tratamiento de enfermedades que incluyen la enfermedad cardíaca (p. ej., enfermedad cardíaca isquémica, insuficiencia cardíaca congestiva y enfermedad cardíaca valvular), pulmonar (p. ej., lesión pulmonar aguda, hipertensión pulmonar, fibrosis pulmonar y enfermedad pulmonar obstructiva crónica), hepática (p. ej., insuficiencia hepática aguda y fibrosis hepática y cirrosis), y renal (p. ej., lesión renal aguda y enfermedad renal crónica).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062992606P | 2020-03-20 | 2020-03-20 | |
| PCT/US2021/023222 WO2021188938A1 (en) | 2020-03-20 | 2021-03-19 | Phd inhibitor compounds, compositions, and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022014587A2 true CO2022014587A2 (es) | 2022-10-21 |
Family
ID=75639963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0014587A CO2022014587A2 (es) | 2020-03-20 | 2022-10-14 | Compuestos inhibidores de phd, composiciones y uso |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230159489A1 (es) |
| EP (1) | EP4121426A1 (es) |
| JP (1) | JP2023518262A (es) |
| KR (1) | KR20220156890A (es) |
| CN (1) | CN115515948A (es) |
| AR (1) | AR121621A1 (es) |
| AU (1) | AU2021240044A1 (es) |
| BR (1) | BR112022018878A2 (es) |
| CA (1) | CA3176142A1 (es) |
| CO (1) | CO2022014587A2 (es) |
| IL (1) | IL296632A (es) |
| MX (1) | MX2022011392A (es) |
| TW (1) | TW202140442A (es) |
| WO (1) | WO2021188938A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI822776B (zh) | 2018-05-09 | 2023-11-21 | 美商阿克比治療有限公司 | 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3443308A1 (de) * | 1984-11-28 | 1986-05-28 | Bayer Ag, 5090 Leverkusen | 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel |
| DE102005019712A1 (de) * | 2005-04-28 | 2006-11-09 | Bayer Healthcare Ag | Dipyridyl-dihydropyrazolone und ihre Verwendung |
| DE102006050515A1 (de) * | 2006-10-26 | 2008-04-30 | Bayer Healthcare Ag | Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung |
| WO2008121861A2 (en) * | 2007-03-28 | 2008-10-09 | Xenon Pharmaceuticals Inc. | Pyrazole and pyrrole compounds useful in treating iron disorders |
| WO2010005851A1 (en) * | 2008-07-08 | 2010-01-14 | Xenon Pharmaceuticals Inc. | Combination therapy for treating iron disorders |
| WO2014089364A1 (en) * | 2012-12-06 | 2014-06-12 | Quanticel Pharmaceuticals, Inc | Histone demethylase inhibitors |
| BR112015020350B1 (pt) * | 2013-03-29 | 2023-04-25 | Takeda Pharmaceutical Company Limited | Derivados de 6-(5-hidróxi-1h-pirazol-1-il)nicotinamida, sua composição farmacêutica e seus usos |
| CN106831735B (zh) * | 2017-01-23 | 2019-10-11 | 牡丹江医学院 | 一种治疗骨质疏松的杂环化合物及其制备方法和用途 |
-
2021
- 2021-03-19 TW TW110109980A patent/TW202140442A/zh unknown
- 2021-03-19 CA CA3176142A patent/CA3176142A1/en active Pending
- 2021-03-19 MX MX2022011392A patent/MX2022011392A/es unknown
- 2021-03-19 AR ARP210100694A patent/AR121621A1/es unknown
- 2021-03-19 BR BR112022018878A patent/BR112022018878A2/pt unknown
- 2021-03-19 EP EP21720874.3A patent/EP4121426A1/en active Pending
- 2021-03-19 US US17/906,652 patent/US20230159489A1/en active Pending
- 2021-03-19 KR KR1020227036363A patent/KR20220156890A/ko active Search and Examination
- 2021-03-19 JP JP2022556196A patent/JP2023518262A/ja active Pending
- 2021-03-19 WO PCT/US2021/023222 patent/WO2021188938A1/en active Application Filing
- 2021-03-19 IL IL296632A patent/IL296632A/en unknown
- 2021-03-19 AU AU2021240044A patent/AU2021240044A1/en active Pending
- 2021-03-19 CN CN202180034132.4A patent/CN115515948A/zh active Pending
-
2022
- 2022-10-14 CO CONC2022/0014587A patent/CO2022014587A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022011392A (es) | 2022-12-15 |
| BR112022018878A2 (pt) | 2022-11-29 |
| AR121621A1 (es) | 2022-06-22 |
| IL296632A (en) | 2022-11-01 |
| AU2021240044A1 (en) | 2022-11-17 |
| EP4121426A1 (en) | 2023-01-25 |
| CN115515948A (zh) | 2022-12-23 |
| CA3176142A1 (en) | 2021-09-23 |
| JP2023518262A (ja) | 2023-04-28 |
| US20230159489A1 (en) | 2023-05-25 |
| WO2021188938A1 (en) | 2021-09-23 |
| KR20220156890A (ko) | 2022-11-28 |
| TW202140442A (zh) | 2021-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017526636A5 (es) | ||
| CO2022014587A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| CO2022014490A2 (es) | Compuestos inhibidores de phd, composiciones y uso | |
| CU23967B1 (es) | Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial | |
| ES2545076T3 (es) | Uso del inhibidor de HDAC panobinostat para el tratamiento de mieloma | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| EA201391730A1 (ru) | 3,5-диамино-6-хлор-n-(n-(4-(4-(2-(гексил(2,3,4,5,6-пентагидроксигексил)амино)этокси)фенил)бутил) карбамимидоил)пиразин-2-карбоксамид | |
| PE20210046A1 (es) | Agonistas de fenilpirrolidinona del receptor 2 de formil peptido | |
| JP2009544602A5 (es) | ||
| UY37631A (es) | Inhibidor de la quinasa reguladora de la señal de apoptosis | |
| CO5570670A2 (es) | Pulmonar obstructiva cronica | |
| TNSN07050A1 (fr) | Derives de triazolopyridinylsulfanyle servant d'inhibiteurs de kinase map p38 | |
| JP2008546770A5 (es) | ||
| MA29746B1 (fr) | Nouveaux inhibiteurs macrocycliques de la multiplication du virus de l'hepatite c | |
| CL2023001331A1 (es) | Compuestos de aminoácidos y métodos de uso | |
| CO6361900A2 (es) | Composicion farmaceutica de un potente de hcv para su administración oral | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| PE20061155A1 (es) | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas | |
| RU2005105564A (ru) | Производные бензимидазола и их применение в качестве пролекарств ингибиторов протонного насоса | |
| AR121626A1 (es) | Compuestos inhibidores de phd, composiciones y métodos de uso | |
| RU2010116293A (ru) | Алкилтиопиримидины в качестве антагонистов crth2 | |
| CO5680413A2 (es) | Aminoacidos con afinidad por la proteina c2 delta | |
| JP2007518798A5 (es) | ||
| EP4349332A3 (en) | Matrix metalloproteinase (mmp) inhibitors and methods of use thereof | |
| CL2023002616A1 (es) | Inhibidores del sarcómero cardíaco |